158 related articles for article (PubMed ID: 25862630)
1. Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
Tei H; Miyake H; Fujisawa M
Hum Cell; 2015 Jul; 28(3):114-21. PubMed ID: 25862630
[TBL] [Abstract][Full Text] [Related]
2. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
Kususda Y; Miyake H; Gleave ME; Fujisawa M
Br J Cancer; 2012 Jun; 106(12):1945-52. PubMed ID: 22588555
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation.
Sakai I; Miyake H; Fujisawa M
BJU Int; 2013 Jul; 112(2):E211-20. PubMed ID: 23305097
[TBL] [Abstract][Full Text] [Related]
4. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y
Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration-resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo.
Nishikawa M; Miyake H; Fujisawa M
Urology; 2015 May; 85(5):1215.e1-1215.e7. PubMed ID: 25917740
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice.
Uchida T; Gao JP; Wang C; Satoh T; Itoh I; Muramoto M; Hyodo T; Irie A; Akahoshi T; Jiang SX; Kameya T; Baba S
Mol Urol; 2001; 5(2):71-8. PubMed ID: 11690551
[TBL] [Abstract][Full Text] [Related]
8. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
[TBL] [Abstract][Full Text] [Related]
9. Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
Liu S; Gao M; Wang X; Ding S; Lv J; Gao D; Wang Z; Niu Z
Oncotarget; 2016 Nov; 7(48):79141-79153. PubMed ID: 27816967
[TBL] [Abstract][Full Text] [Related]
10. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
11. Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Karashima T; Komatsu T; Niimura M; Kawada C; Kamada M; Inoue K; Udaka K; Kuroda N; Shuin T
Int J Urol; 2014 Jul; 21(7):702-6. PubMed ID: 24571181
[TBL] [Abstract][Full Text] [Related]
12. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Benitez A; Yates TJ; Shamaldevi N; Bowen T; Lokeshwar VB
J Urol; 2013 Jul; 190(1):285-90. PubMed ID: 23228386
[TBL] [Abstract][Full Text] [Related]
13. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
14. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
15. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
[TBL] [Abstract][Full Text] [Related]
17. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
18. Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway.
Zhang H; Sheng L; Tao J; Chen R; Li Y; Sun Z; Qian W
Int J Oncol; 2016 Dec; 49(6):2498-2506. PubMed ID: 27779645
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Biochem; 2013 Aug; 114(8):1819-31. PubMed ID: 23463670
[TBL] [Abstract][Full Text] [Related]
20. Introducing the clusterin gene into human renal cell carcinoma cells enhances their metastatic potential.
Miyake H; Gleave ME; Arakawa S; Kamidono S; Hara I
J Urol; 2002 May; 167(5):2203-8. PubMed ID: 11956479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
